Since 2011, when the United States Food and Drug Administration (U.S. FDA) approved ipilimumab (Yervoy®) for malignant melanoma, several immune-checkpoint inhibitors have been granted marketing authorisation. Do you know all the indications? MediPaper made an overview of all the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.
What is new in the treatment of haematologic malignancies? Read our haematology blog and learn more about the latest advancements in the treatment of haematologic malignancies.
The United States Food and Drug Agency (US FDA) require the development of companion diagnostics (CDx). CDx can help to identify patients at risk and guide patient selection. Moreover, it serves as a marker for treatment outcome. Thus enabling physicians to better balance safety with efficacy. The US FDA motivates the development of a CDx in early stages of clinical studies.
ESMO 2016 nivolumab data in Late Breaking Abstracts is focused on two studies in non-small cell lung cancer (NSCLC; CheckMate 026 and a neoadjuvant study), one presentation in combination with ipilimumab in stage 3 palpable melanoma (OpACIN trial), and finally a presentation in metastatic urothelial carcinoma (mUC; CheckMate-275 trial).